Compare Banco Santander SA (SAN) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Santander SA vs Sana Biotechnology Inc — how do they compare? Banco Santander SA trades at $13.5 (market cap $192.86B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Banco Santander SA is far larger — about 230.5× Sana Biotechnology Inc's market cap, and Banco Santander SA pays a 2.06% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Banco Santander SA for 55 Days and Sana Biotechnology Inc for 23 Days on average.
| SAN | SANA | |
|---|---|---|
Market Cap | $192.86B | $836.71M |
Volume | 10,644,519 | 4,507,444 |
Sector | Financials | Health |
52-Week High | $15.05 | $5.92 |
52-Week Low | $9.65 | $2.68 |
Typical Hold Time | 55 Days | 23 Days |
Enterprise Value | $360.86B | $749.96M |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Banco Santander (SAN) trades at $13.49, down 1.24% with bearish technical signals, though fundamentals show strength with 26.25% net margins and 16.07% ROE. Recent earnings show mixed quarterly performance, beating in Q1 but missing in Q2. The company completed the Webster Bank acquisition in August 2026, expanding U.S. presence and driving record profits. Cash flow trends remain negative, but revenue and net income have grown steadily from 2022-2026.
Outlook remains cautiously optimistic with 64% analyst buy ratings supporting growth potential from strategic acquisitions and digital transformation. Key risks include negative cash flow trends, high debt levels at $288B, and economic sensitivity. The stock offers value at 13.55 P/E but requires monitoring of operational cash flow recovery and integration of recent acquisitions.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
